Últimas noticias sobre Daiichi Sankyo Co (OTC:DSNKY) Bolsa

DAIICHI SANKYO

Daiichi Sankyo Co

Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2024, approximately one quarter of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates, or ADCs. Its three lead ADCs are Enhertu (HER2), Datroway (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first US approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer.

Analyst Color

Asia

Equities

Long Ideas

News

Global

Markets

Analyst Ratings

Trading Ideas

ALCPF

DSKYF

DSNKY

HTHIF

HTHIY

HXSCF

HXSCL

NIPNF

NVDA

Descubre las 10 acciones asiáticas que Macquarie recomienda como las mejores oportunidades de compra en medio de la agitación global.

10 acciones asiáticas para comprar en medio de la volatilidad del mercado

DAIICHI SANKYO S/ADR by Daiichi Sankyo Co., Ltd.

Daiichi Sankyo Co Ltd

Press Releases

Alteogen enters into an Exclusive License Agreement to Develop and Commercialize Subcutaneous ENHERTU® Enabled by Alteogen's Hybrozyme™ Technology

GRAIL Announces First Patient Tested With Blood-Based Assay in Global Phase 3 Adjuvant Lung Cancer Study

GRAL

TYO:4568

Comments

Daiichi Sankyo Co

Noticias

Últimas noticias sobre Daiichi Sankyo Co (OTC:DSNKY) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL